At 22.2% CAGR, Europe Organoids Services Market is Projected to be Worth US$ 5,016.03 Million by 2031, says Business Market Insights

According to Business Market Insights research, the Europe organoids services market was valued at US$ 1,233.51 million in 2024 and is expected to reach US$ 5,016.03 million by 2031, registering a CAGR of 22.2% from 2024 to 2031. Integration of artificial intelligence and increasing key developments are among the critical factors attributed to driving the Europe organoids services market growth.

The progress of the healthcare sector has led to a rise in the demand for organoids across the world. This increased demand contributes to new product developments, acquisitions, partnerships, product launches, and approvals on a global level. Major market players are involved in activities to ensure the innovation and development of efficient services and products. A few of the recent key developments are listed Below:

In June 2024, Molecular Devices, LLC. formally opened its purpose-built facility in Cardiff, UK. The multimillion-pound facility was designed to accommodate the exclusive bioprocess workflow and innovative bioreactor technology of the business, allowing for the large-scale, quality-controlled production of PDOs. Substantial amounts of repeatable PDOs that are 3D-ready are available as a custom service and are cryopreserved in a manner that is ready for analysis. Researchers can defrost, plate, and use these products as needed.

In May 2024, InSphero, a biotech company, signed a partnership agreement with Genome Biologics, Frankfurt. In this partnership, InSphero will receive the exclusive global rights to commercialize Genome Biologics' 3D Cardiac Organoid Platform. The platform provides accurate, scalable, and disease-specific organoid models for creating novel treatments, placing it at the forefront of heart disease research.

In January 2024, HUB Organoids (HUB) launched IntegriGut Screen services for the global market. This screening service employs IBD patient-derived organoid monolayers—PDO Monolayers—to aid in the availability of high-quality human data on epithelial barrier function, in turn accelerating the development of novel IBD therapies.

In July 2023, Molecular Devices launched a custom organoid line expansion service with unique bioprocess technology for high-throughput applications. In February 2023, Molecular Devices, LLC., and HUB Organoids (HUB) announced a strategic collaboration to contribute to the continued development of next-generation 3D biology technologies that enable step-change reduction in preclinical to clinical drug attrition.

In December 2022, Molecular Devices, LLC. acquired Cellesce Ltd. This acquisition focuses on producing large-scale PDOs for various purposes, including drug screening, through contract development and production services.

In August 2021, STEMCELL Technologies and Hubrecht Organoid Technology (HUB) signed an agreement. As a part of this agreement, STEMCELL's Contract Assay Services division began providing its tissue-derived organoids, such as lung, intestinal, liver organoids, for pre-clinical toxicology screening and non-cancer drug development services to HUB. These services would facilitate the integration of organoids into preclinical testing programs by researchers and drug development organizations to aid in the faster and more economical launch of new therapies.

In May 2020, CELLINK collaborated with AstraZeneca to provide advanced 3D bioprinted liver organoids for drug discovery purposes in metabolic diseases, renal, and cardiovascular diseases. This collaboration allowed AstraZeneca to use Extra Cellular Matrix and Laminin-based bioinks from CELLINK. These are novel and patent-pending bioinks that allow human cells to proliferate and behave similarly to their behavior in the human body.

In February 2020, InnoSer and Organotherapeutics announced a collaboration to provide midbrain organoids for drug discovery and screening. This collaboration was meant to make midbrain organoids commercially available as a platform for Parkinson's disease research.

Such key developments, launches, and strategic collaborations among market players create ample opportunities for the organoid services market growth.

On the contrary, the dearth of skilled professionals hampers the growth of the Europe organoids services market.

By type, the Europe organoids services market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine held 23.1% share of Europe Organoids Services Market share in 2024, amassing US$ 284.96 million. It is projected to garner US$ 1,140.24 million by 2031 to register 21.9% CAGR during 2024–2031.

By application, the Europe organoids services market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology disease held 29.8% share of Europe organoids services market share in 2024, amassing US$ 367.44 million. It is projected to garner US$ 1,554.86 million by 2031 to register 22.9% CAGR during 2024–2031.

By source, the Europe organoids services market is bifurcated into pluripotent stem cells and organ specific adult stem cell. The pluripotent stem cells held 73.0% share of Europe organoids services market share in 2024, amassing US$ 900.93 million. It is projected to garner US$ 3,763.97 million by 2031 to register 22.7% CAGR during 2024–2031.

Based on country, the Europe organoids services market is categorized into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.1% share of Europe organoids services market in 2024. It was assessed at US$ 359.44 million in 2024 and is likely to hit US$ 1,447.63 million by 2031, registering a CAGR of 22.0% during 2024–2031.

Key players operating in the organoids services market are CUSABIO TECHNOLOGY LLC; Cyprio; Eurofins Scientific SE; HUB Organoids B.V. (Hubrecht Organoid Technology); InnoSer; InSphero; LABTOO; Molecular Devices, LLC.; Oncodesign Services; and Sino Biological Inc., among others.

• In May 2024: InSphero AG is pleased to announce its exclusive commercialization partnership with Genome Biologics, based in Frankfurt, Germany. This partnership will grant InSphero exclusive global rights to commercialize Genome Biologics' revolutionary 3D Cardiac Organoid Platform. This platform is at the forefront of cardiac disease research, offering precise, scalable, and disease-specific organoid models that are crucial for the development of novel therapeutics.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com